Specialised Therapeutics (ST) has entered an exclusive agreement to license Korea-based CanariaBio’s oregovomab for treating ovarian cancer.
The cancer therapy will be licensed for Australia, New Zealand and selected countries in South East Asia.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
A monoclonal antibody, oregovomab is currently being analysed in a global Phase III clinical trial, the FLORA-5 study.
Oregovomab is being evaluated along with chemotherapy agents carboplatin and paclitaxel in advanced ovarian cancer patients.
The final results from the trial will be available in 2025.
ST will oversee the complete commercial, medical, regulatory and distribution works of oregovomab in Australia, Brunei, Malaysia, New Zealand, Singapore, Thailand and Vietnam.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataCanariaBio will also manage the production of the supply of the antibody to ST.
ST CEO Carlo Montagner stated: “ST has a portfolio of anti-cancer therapies targeting multiple solid tumours with the exception of ovarian cancer, and now oregovomab becomes our first ovarian cancer agent.
“Despite great advances in recent years, there remains a high unmet need in all our regions to treat this patient population. We look forward to working closely with our new partners at CanariaBio and pending the results of the pivotal Phase III registration study, making oregovomab available to eligible patients.”
According to the findings from a Phase II trial, treatment with oregovomab plus chemotherapy offered improvement in progression-free survival of almost 30 months versus chemotherapy alone.
In August 2023, ST licensed Treeway’s TW001 for the treatment of amyotrophic lateral sclerosis.
